Avidity Biosciences, Inc. announced that final results from the Phase 1/2 MARINA trial of delpacibart etedesiran, an antibody oligonucleotide conjugate targeting myotonic dystrophy type 1, have been published in The New England Journal of Medicine, representing the first peer reviewed clinical evidence that targeted siRNA delivery to skeletal muscle can reduce toxic DMPK mRNA and produce aligned functional signals in this disease setting

Why targeted siRNA delivery to skeletal muscle represents a structural breakthrough rather than an incremental DM1 advance

For decades, myotonic dystrophy type 1 has occupied an unusual position in neuromuscular drug development. The genetic mechanism is well defined, the causal toxic RNA species is known, and downstream splice defects have been mapped in detail. Yet despite this clarity, therapeutic progress has stalled largely because skeletal muscle has proven resistant to efficient and selective nucleic acid delivery. The MARINA data matter because they demonstrate that this delivery barrier is no longer theoretical. By using an antibody oligonucleotide conjugate that leverages transferrin receptor 1 mediated uptake, Avidity Biosciences, Inc. has shown that systemically administered siRNA can reach muscle tissue at levels sufficient to alter disease biology.

This is not a marginal improvement over prior antisense approaches. It is a validation of a delivery paradigm that many in the field have pursued unsuccessfully. Industry observers see this as a platform inflection rather than a single asset story, with implications extending well beyond DM1 into other muscle driven genetic disorders.

What the MARINA trial data reveal about the threshold for clinically meaningful DMPK mRNA reduction in adult DM1 patients

The reported approximately 40 percent mean reduction in DMPK mRNA across treated participants sits in an important middle ground. It is not complete suppression, nor does it represent gene level correction. However, it appears sufficient to relieve downstream RNA toxicity to a degree that produces measurable splice correction and functional trends. Clinicians tracking the field note that this finding challenges the assumption that near complete knockdown is required to generate benefit in adult DM1, a disease characterized by long established pathology.

At the same time, the data do not yet define an optimal threshold. Whether deeper or more sustained knockdown would translate into materially greater clinical benefit remains unknown, and the dose related safety signals observed at higher exposures suggest that pushing the biology harder may come with tradeoffs.

How splice correction and functional signals begin to close the long-standing gap between DM1 biology and outcomes

One of the persistent frustrations in DM1 development has been the disconnect between molecular changes and patient experience. Prior programs have often demonstrated biomarker movement without convincing functional improvement, or symptomatic effects without clear mechanistic anchoring. The MARINA dataset stands out because molecular knockdown, splice normalization, objective functional measures, and patient reported outcomes move in the same direction.

While the trial was not powered for efficacy, the coherence of these signals matters. It suggests that the intervention is acting on the disease mechanism rather than merely producing nonspecific neuromuscular effects. For clinicians, this alignment increases confidence that observed changes are not artefactual, even if the magnitude and durability of benefit remain to be proven.

Why early functional improvements in DM1 remain difficult to interpret without longer-duration disease trajectory data

Despite encouraging trends, caution is warranted. Functional endpoints such as video hand opening time, quantitative muscle testing, and mobility assessments are inherently variable and sensitive to learning effects, motivation, and day to day fluctuations. In a six month Phase 1/2 study, distinguishing true disease modification from short term functional adaptation is challenging.

Regulatory watchers and clinicians alike will therefore place significant weight on longer duration data. Demonstrating slowed progression relative to natural history, rather than transient improvement, will be essential. This is particularly relevant in DM1, where disease progression can be nonlinear and heterogeneous across patients.

What safety findings at higher doses suggest about therapeutic windows for antibody oligonucleotide conjugates

Safety remains one of the most important unresolved questions. Although most treatment emergent adverse events were mild or moderate, the occurrence of serious adverse events at higher dose levels, including one deemed drug related, highlights that the therapeutic window may not be unlimited. For a chronic disease requiring repeated dosing, even infrequent serious events can materially affect benefit risk assessment.

Industry observers note that this is not unexpected for a first generation muscle targeted RNA therapy. However, it reinforces the need for careful dose selection, long term monitoring, and clear understanding of cumulative exposure risks as development moves into Phase 3 and beyond.

How delpacibart etedesiran compares with prior antisense and small-molecule approaches that failed to translate

Relative to earlier antisense oligonucleotide programs, delpacibart etedesiran differentiates itself primarily through delivery efficiency rather than target novelty. Small molecule approaches aimed at modulating splicing or downstream pathways have struggled to produce consistent benefit, while traditional antisense therapies have been limited by poor muscle penetration.

By contrast, the antibody oligonucleotide conjugate approach directly addresses the delivery problem, enabling engagement of the causal RNA target within muscle cells. This positions delpacibart etedesiran closer to the root cause of disease than symptomatic or downstream modulators, even if its ultimate effect proves partial rather than curative.

What regulators are likely to scrutinise in Phase 3 as delpacibart etedesiran moves from signal to proof

The global Phase 3 HARBOR study represents the true test of whether MARINA’s promise translates into regulatory approvability. Regulators are expected to focus on the robustness of the primary endpoint, video hand opening time, its clinical meaningfulness, and the consistency of secondary measures including muscle strength and activities of daily living.

Equally important will be safety over a longer treatment horizon and across a broader patient population, including adolescents. While expedited designations reflect unmet need, they do not lower evidentiary standards. Clear demonstration of benefit that matters to patients will remain the decisive factor.

Why commercial adoption will hinge on durability, manufacturing scalability, and payer definitions of disease modification

Even with regulatory approval, commercial success is not guaranteed. Payers are likely to scrutinise durability of benefit, particularly given the expected cost of an antibody oligonucleotide conjugate therapy. Demonstrating sustained functional improvement or slowed progression over years, rather than months, will be critical to justify reimbursement.

Manufacturing scalability also represents a nontrivial risk. Combining monoclonal antibody production with oligonucleotide conjugation introduces complexity that few companies have commercialised at scale. Any constraints on supply, cost, or consistency could affect uptake, especially outside major markets.

What clinicians and industry observers will watch most closely as the Phase 3 HARBOR readout approaches

As the field looks toward the second half of 2026, attention will focus on whether Phase 3 data confirm MARINA’s internal consistency and extend it over time. Clinicians will watch for clear signals of slowed disease progression, regulators will assess benefit risk balance in a chronic setting, and industry observers will evaluate whether the antibody oligonucleotide conjugate platform can support multiple indications.

In that broader context, the New England Journal of Medicine publication marks more than a milestone for one program. It signals that muscle targeted RNA therapy has crossed a credibility threshold. The remaining question is not whether the biology can be engaged, but whether that engagement can be translated into durable, scalable, and clinically meaningful benefit for patients living with myotonic dystrophy type 1.

  Antibody Oligonucleotide Conjugates, Avidity Biosciences, delpacibart etedesiran, Myotonic Dystrophy Type 1, neuromuscular disease, RNA therapeutics